The role of procalcitonin in sepsis
Phase 2
- Conditions
- Condition 1: Sepsis. Condition 2: procalcitonin.Sequelae of infectious and parasitic diseasesAbnormal findings on examination of blood, without diagnosisB90-B94R70-R79
- Registration Number
- IRCT201102065774N1
- Lead Sponsor
- vice-chancellor for research of Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
All patients with clinical findings suggesting sepsis, All patients with clinical findings of systemic inflammatory response syndrome
Exclusion criteria:
All patients with clinical findings of systemic inflammatory response syndrome from non bacterial origin, viral or parasitic infections, patients who receive corticosteroids on immunosuppressive drugs, history of immunodeficiency, patient with central venous catheter and premature infant
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Procalcitonin. Timepoint: before and 6 hr and 24 hr after empiric antibiotic administration. Method of measurement: Immunoluminoassay ng/mL.
- Secondary Outcome Measures
Name Time Method Antibiogram. Timepoint: One time. Method of measurement: Resistantant, sensitive.;Empiric antibiotic. Timepoint: one time, after blood sampling withdrawn. Method of measurement: based on united state infectious disease guideline.;Time of clinical sign improved. Timepoint: Daily. Method of measurement: Clinical sign(fever).;Prognosis(death). Timepoint: Death. Method of measurement: Clinically.;Prognosis(life). Timepoint: Life. Method of measurement: Clinically.;Thyroid tumor. Timepoint: One time. Method of measurement: Clinical and laboratory investigation.;Immunosuppression. Timepoint: One time. Method of measurement: Clinical and laboratory investigation.